Akademik Veri Yönetim Sistemi
8th INTERNATIONAL CONGRESS on APPLIED BIOLOGICAL SCIENCES , Priştine, Kosova, 13 - 16 Eylül 2023, ss.41
Lung cancer ranks highest as the primary cause of cancer-related deaths globally. There are two
primary categories of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). NSCLC makes up about 85% of all lung cancer cases. Currently, the standard treatment
options for NSCLC in medical practice are chemotherapy and surgery. However, these approaches have
limited efficacy for patients diagnosed with advanced NSCLC. It is crucial to recognize the significance
of discovering new therapeutic agents to effectively treat this deadly form of cancer. Recently,
researchers have been increasingly interested in natural products and especially compounds derived
from plants, which have a high potential to be anti-tumor agents. Vitexin (apigenin-8-C-glucoside), a
flavonoid, is one of them. Vitexin has recently been known to have anti-cancer, antioxidant, anti
inflammatory, anti-nociceptive, anti-hypertensive, anti-depressant-like effects and anti-viral activities.
In this study, the anticancer effects of vitexin were investigated on the A549 human lung
adenocarcinoma cell line. Cisplatin was evaluated as a positive control. Cytotoxicity and IC50 values of
vitexin in A549 cells were determined by MTT assay. Various concentrations of vitexin (15.62-2000
μM) effectively reduced cell viability in A549 cell line in a dose-dependent manner. IC50 values of
vitexin and cisplatin were determined as 186,67 μM and 29,11 μM in A549 cells for 24h respectively.
In addition, early phase apoptosis and caspase 3 activity also increased in a time-dependent manner.
This results show that vitexin had selective anticancer activity in A549 cell line.